Business
Travere Therapeutics Provides Corporate Update and 2026 Outlook
U.S. FILSPARI reaches all-time highs of 908 new PSFs and net product sales of approximately $103 million in 4Q 2025 Company positioned for successful
About this update from Travere Therapeutics, Inc.
[{"type":"text","content":"\nU.S. FILSPARI reaches all-time highs of 908 new PSFs and net product sales of approximately $103 million in 4Q 2025\n\n\nCompany positioned for successful commercial launch of FILSPARI in FSGS, if approved\n\n\nPivotal Phase 3 HARMONY Study of pegtibatinase in classical HCU to restart in 1Q 2026\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nTravere Therapeutics, Inc. (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects total U.S. net product sales for the fourth quarter of 2025 to be approximately $127 million. For the fiscal year 2025, the Company expects total U.S. net product sales to be approximately $410 million. The Company ended 2025 with approximately $323 million in cash, cash equivalents, and marketable securities. The Company also provided an update on key corporate, clinical, and regulatory development initiatives, including anticipated 2026 milestones.\n\n\n“The fourth quarter closed out an exceptional year of commercial execution with FILSPARI, as our teams were able to reach a record number of patients with IgAN, reinforcing its role as foundational therapy,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “As we move into 2026, we are focused on sustaining this momentum while preparing for a successful commercial launch of FILSPARI in FSGS, which, if approved, would be the first approved medication for these patients facing potential kidney failure. In addition, we are well-positioned to restart the pivotal Phase 3 HARMONY Study of pegtibatinase in the first quarter now that we have further optimized our manufacturing process. This marks an important next step in advancing our pipeline and delivering the first potentially disease-modifying therapy for people living with classical HCU.”\n\n\nProgram Updates and Anticipated 2026 Milestones\n\n\nFILSPARI® (sparsentan) – IgA Nephropathy (IgAN)\n\n\n\n908 new patient start forms (PSFs) were received during the quarter, driven by continued demand from repeat and new prescribers.\n\n\n\nPreliminary U.S. net product sales of FILSPARI totaled approximately $103 million in the fourth quarter of 2025, representing 108% growth year-over-year; approximately $322 million for the full year 2025.\n\n\n\nIn October 2025, the Company received a $40 million milestone payment from its collaborator C...